PVT1 and cancer: Interfering with one of the PVT1 promoters by targeted CRISPRi or by deletion of the alternative promoters, as is found in human cancers, prevents the PVT1 promoter from capturing the enhancer activity, which is therefore redirected to the MYC gene causing it to be upregulated and thus promoting growth (Cho et al., 2018).